Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
暂无分享,去创建一个
A. Bardelli | F. Di Nicolantonio | A. Sartore-Bianchi | S. Siena | J. Balfour | Federica Di Nicolantonio | Alberto Bardelli | Andrea Sartore-Bianchi | Salvatore Siena | Julia Balfour
[1] Vitor Mendes Pereira,et al. In Reply. , 2011, Neurosurgery.
[2] Sabine Tejpar,et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[5] Linda Mol,et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[6] E. Van Cutsem,et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.
[7] L. Mazzucchelli,et al. Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.
[8] S. Tejpar,et al. 6005 PIK3CA, BRAF and KRAS mutations and outcome prediction in chemorefractory metastatic colorectal cancer (mCRC) patients treated with EGFR targeting monoclonal antibodies (MoAbs): results of a European Consortium , 2009 .
[9] U. Harmenberg,et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Sabine Tejpar,et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.
[11] G. Fontanini,et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer , 2009, British Journal of Cancer.
[12] J. Meyerhardt,et al. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer , 2009, British Journal of Cancer.
[13] L. Pollak. Moyamoya disease and moyamoya syndrome. , 2009, The New England journal of medicine.
[14] E. Van Cutsem,et al. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Lindebjerg,et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] D. Lambrechts,et al. PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.
[17] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Ychou,et al. TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy , 2009, British Journal of Cancer.
[19] M. Ychou,et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Francesca Molinari,et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. , 2009, Cancer research.
[21] Seta Shahin,et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Bokemeyer,et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] L. Heasley,et al. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. , 2008, Molecular biology of the cell.
[24] F.A.M. Bordonaba,et al. Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer , 2009 .
[25] Giampietro Gasparini,et al. K-ras mutations and cetuximab in colorectal cancer. , 2009, The New England journal of medicine.
[26] S. Andreola,et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] L. Mazzucchelli,et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] A. Santoro,et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[30] E. Van Cutsem,et al. Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study , 2008, Clinical Cancer Research.
[31] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Ryan,et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells , 2008, Clinical Cancer Research.
[33] P. Laurent-Puig,et al. K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy , 2008, Clinical Cancer Research.
[34] Giampietro Gasparini,et al. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications , 2008, Nature Clinical Practice Oncology.
[35] P. Harari,et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members , 2008, Oncogene.
[36] S. Misbah,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[37] C. Stroh,et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) , 2008 .
[38] J. Tabernero,et al. Phase III study (PRIME/20050203) of panitumumab (pmab) with FOLFOX compared with FOLFOX alone in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Pooled safety data , 2008 .
[39] F. Lordick,et al. Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results , 2008 .
[40] V. Adamo,et al. Early Magnesium Reduction in Advanced Colorectal Cancer Patients Treated with Cetuximab Plus Irinotecan as Predictive Factor of Efficacy and Outcome , 2008, Clinical Cancer Research.
[41] S. Shak,et al. Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer , 2008 .
[42] Pierre Laurent-Puig,et al. Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.
[43] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Daniel J. Freeman,et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. , 2008, Clinical colorectal cancer.
[45] M. Moroni,et al. EGFR FISH in colorectal cancer: what is the current reality? , 2008, The Lancet. Oncology.
[46] Dongyun Yang,et al. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. , 2008, Cancer research.
[47] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] V. Catalano,et al. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Sanjay Goel,et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. , 2008, Cancer research.
[50] Quynh-Thu Le,et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. , 2008, The New England journal of medicine.
[51] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[52] G. Tortora,et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs , 2008, British Journal of Cancer.
[53] M. Korc,et al. Shining the spotlight on shed kras in pancreatic cancer , 2008, Cancer biology & therapy.
[54] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[55] D. Coradini,et al. PIK3CA cancer mutations display gender and tissue specificity patterns , 2008, Human mutation.
[56] R. Frazzi,et al. Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines , 2008, Molecular Cancer Therapeutics.
[57] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] G. Qiao,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2008 .
[59] P. Jänne,et al. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] G. Fountzilas,et al. Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study , 2008, BMC Cancer.
[61] F. Bertucci,et al. A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment , 2008, BMC Cancer.
[62] R. Ferris,et al. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. , 2007, Archives of otolaryngology--head & neck surgery.
[63] E. Van Cutsem,et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab , 2007, British Journal of Cancer.
[64] Dongsheng Tu,et al. Cetuximab for the treatment of colorectal cancer. , 2007, The New England journal of medicine.
[65] F. Cavalli,et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients , 2007, British Journal of Cancer.
[66] A. Musolino,et al. 522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy , 2007 .
[67] J. Berlin,et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer , 2007, Cancer.
[68] R. Labianca,et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Berlin,et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] S. Groshen,et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] M. Moroni,et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] P. Jänne,et al. EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer , 2007 .
[73] H. Lenz,et al. EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144) , 2007 .
[74] J. Hecht,et al. Panitumumab activity in metastatic colorectal cancer (mCRC) patients (pts) with low or negative tumor epidermal growth factor receptor (EGFr) levels: An updated analysis , 2007 .
[75] F. Ciardiello,et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data , 2007 .
[76] J. Berlin,et al. Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials , 2007 .
[77] P. Philip,et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study , 2007 .
[78] C. Köhne,et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .
[79] C. Bokemeyer,et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study , 2007 .
[80] Jin-Hwang Liu,et al. Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma , 2007, Clinical Cancer Research.
[81] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Roy S Herbst,et al. KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.
[83] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] E. Van Cutsem,et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. , 2007, The Lancet. Oncology.
[86] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[87] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[88] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[89] Alona Muzikansky,et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.
[91] Jin-Hwang Liu,et al. Epidermal Growth Factor Receptor R 497 KPolymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma , 2007 .
[92] E. Van Cutsem,et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] J. Baselga,et al. The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy , 2006, Clinical Cancer Research.
[94] S. Groshen,et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab , 2006, Pharmacogenetics and genomics.
[95] G. Fountzilas,et al. Predictive markers for the treatment of colorectal cancer with cetuximab. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] C. Létoublon,et al. EGFR in colorectal cancer: more than a simple receptor. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] G. Tortora,et al. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[98] A. Russo,et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[99] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[100] Z. Hua. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .
[101] Stephen L. Abrams,et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. , 2006, Advances in enzyme regulation.
[102] D. Larsimont,et al. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer. , 2005, Seminars in oncology.
[103] A. Bardelli,et al. Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. , 2005, Cancer research.
[104] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[105] M. Moroni,et al. Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] David G P Allan. Nimotuzumab: evidence of clinical benefit without rash. , 2005, The oncologist.
[107] W. Gerald,et al. Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study , 2005, Modern Pathology.
[108] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] M. Ostland,et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[110] Mayumi Ono,et al. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.
[111] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] S. Schwartz,et al. The prevalence of PIK3CA mutations in gastric and colon cancer. , 2005, European journal of cancer.
[113] S. Groshen,et al. Molecular determinants of cetuximab efficacy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] Silvia Benvenuti,et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.
[115] L. Schwartz,et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] L. Seymour,et al. A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer , 2005, Investigational New Drugs.
[117] H. Varmus,et al. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.
[118] P. V. van Diest,et al. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[119] K. Kinzler,et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. , 2004, The New England journal of medicine.
[120] A. Russo,et al. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations. , 2004, Biochemical and biophysical research communications.
[121] R. Berardi,et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] L. Ellis. Angiogenesis and its role in colorectal tumor and metastasis formation. , 2004, Seminars in oncology.
[123] P M Harari,et al. Epidermal growth factor receptor inhibition strategies in oncology. , 2004, Endocrine-related cancer.
[124] L. Ellis. Epidermal growth factor receptor in tumor angiogenesis. , 2004, Hematology/oncology clinics of North America.
[125] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] R. Figlin,et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] Xiaoling Li,et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study , 2004, Modern Pathology.
[128] A. Santoro,et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.
[129] J. Koropatnick,et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[132] C. Arteaga,et al. Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. , 2004, Seminars in oncology.
[133] G. Tortora,et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy , 2004, Clinical Cancer Research.
[134] D. Bishop,et al. Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas , 2003, Molecular pathology : MP.
[135] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[136] R. Labianca,et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[137] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[138] A. Tarnawski,et al. Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.
[139] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[140] 이석호,et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.
[141] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[142] J. Herman,et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] Notes , 1989, Fin-de-Siècle Splendor.
[144] K. Furuse. [Phase III study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[145] Mackay,et al. Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[146] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[147] B. Iacopetta,et al. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short‐term prognostic indicators of survival , 1994, International journal of cancer.
[148] M. Morrin,et al. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. , 1994, Gut.
[149] S. Rodenhuis,et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.
[150] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[151] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.